Peptides for Sleep

Community reports on peptides used for sleep improvement — CJC-1295, ipamorelin, epitalon, and more. Anonymous accounts of sleep quality changes, protocols, and timing.

6 anonymous reports

Community Q&A

What peptides are used for improving sleep?
Community accounts for sleep improvement cluster heavily around GH secretagogues — CJC-1295 + ipamorelin is the most frequently cited combination, with improved sleep depth described as the earliest and most consistent effect. Epitalon appears in longevity-focused sleep accounts, often described as improving sleep architecture and circadian rhythm over weeks. DSIP (delta sleep-inducing peptide) appears in a smaller subset of accounts with variable reported results. The near-universal dosing pattern for sleep: pre-bed injection, 30–60 minutes before sleep.
How quickly does CJC-1295 and ipamorelin improve sleep?
Sleep improvement is consistently the first effect users report on the CJC-1295 + ipamorelin stack — and the fastest. Community accounts describe noticeably deeper, more restorative sleep within 3–7 days of starting, often before any body composition changes are apparent. The recurring description: falling asleep faster, fewer wake-ups, and waking feeling more rested. Vivid dreams appear in a subset of accounts, most frequently in the first 2–4 weeks. This early sleep signal is frequently cited as the primary confirmation that the stack is working.
Does ipamorelin alone improve sleep?
Community accounts using ipamorelin alone (without CJC-1295) still describe sleep benefits, though typically described as less pronounced than the combined stack. The mechanism cited in accounts is the GH pulse at sleep onset — ipamorelin's clean GH release without cortisol or prolactin spikes is specifically noted as producing restful sleep rather than disrupted sleep. Accounts that tried other GHRPs (GHRP-2, GHRP-6) before switching to ipamorelin frequently cite better sleep as a key reason for the switch.
What peptides help with sleep disorders or insomnia?
Community accounts addressing sleep disorders rather than general sleep quality are less common but present. Epitalon accounts focusing on insomnia describe gradual normalisation of sleep timing over 2–4 weeks of a cycle. Selank appears in a subset of accounts where anxiety was driving poor sleep — described as reducing pre-sleep rumination. DSIP accounts for insomnia show the most variable outcomes in community reports, with roughly equal numbers describing benefit and no effect. Most accounts treating sleep as a primary goal use CJC-1295 + ipamorelin as a starting point.